| アブストラクト | INTRODUCTION: Identifying individual characteristics or underlying conditions linked to adverse drug reactions (ADRs) can help optimise the benefit-risk ratio for individuals. A systematic evaluation of statistical methods to identify subgroups potentially at risk using spontaneous ADR report datasets is lacking. OBJECTIVES: In this study, we aimed to assess concordance between subgroup disproportionality scores and European Medicines Agency Pharmacovigilance Risk Assessment Committee (PRAC) discussions of potential subgroup risk. METHODS: The subgroup disproportionality method described by Sandberg et al., and variants, were applied to statistically screen for subgroups at potential increased risk of ADRs, using data from the US FDA Adverse Event Reporting System (FAERS) cumulative from 2004 to quarter 2 2021. The reference set used to assess concordance was manually extracted from PRAC minutes from 2015 to 2019. Mentions of subgroups presenting potential differentiated risk and overlapping with the Sandberg method were included. RESULTS: Twenty-seven PRAC subgroup examples representing 1719 subgroup drug-event combinations (DECs) in FAERS were included. Using the Sandberg methodology, 2 of the 27 could be detected (one for age and one for sex). No subgroup examples for pregnancy and underlying condition were detected. With a methodological variant, 14 of 27 examples could be detected. CONCLUSIONS: We observed low concordance between subgroup disproportionality scores and PRAC discussions of potential subgroup risk. Subgroup analyses performed better for age and sex, while for covariates not well-captured in FAERS, such as underlying condition and pregnancy, additional data sources should be considered. |
|---|
| 投稿者 | Mahaux, Olivia; Powell, Greg; Haguinet, Francois; Sobczak, Paulina; Saini, Namrata; Barry, Allen; Mustafa, Amira; Bate, Andrew |
|---|
| 組織名 | Safety Innovation and Analytics, GSK, Wavre, Belgium. olivia.x.mahaux@gsk.com.;Safety Innovation and Analytics, GSK, Durham, NC, USA.;Safety Innovation and Analytics, GSK, Wavre, Belgium.;Safety Evaluation and Risk Management, GSK, Warsaw, Poland.;Safety Evaluation and Risk Management, GSK, Bangalore, India.;University of North Carolina, Chapel Hill, NC, USA.;Safety Innovation and Analytics, GSK, London, UK.;London School of Hygiene and Tropical Medicine, University of London, London, UK. |
|---|
